UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    May

    31

    Go Behind The Mystery of Myasthenia Gravis On Myasthenia Gravis Awareness Month

    Read More Share:linkedin| twitter| email

    May

    31

    Empowering the Hidradenitis Suppurativa Community: UCB's Triple Approach

    Read More Share:linkedin| twitter| email

    May

    23

    UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa

    Read More Share:linkedin| twitter| email

    May

    10

    Moms Really Can Do It All - Meet Tracy: a Mom, Caregiver, Neuroscientist, and Advocate in the Rare Disease Community

    Read More Share:linkedin| twitter| email

    May

    06

    Evolving Expectations for Arthritis Management

    Read More Share:linkedin| twitter| email

    Apr

    12

    UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting

    Read More Share:linkedin| twitter| email

    Apr

    11

    Our Leadership and Legacy in Epilepsy and Rare Syndromes

    Read More Share:linkedin| twitter| email

    Apr

    10

    Striving to Make HStory: UCB’s Mission to Raise Awareness for Hidradenitis Suppurativa

    Read More Share:linkedin| twitter| email

    Apr

    10

    UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

    Read More Share:linkedin| twitter| email

    Apr

    04

    FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)